No Detail Found!

Panretinal Photocoagulation Plus Intravitreal Bevacizumab Versus Panretinal Photocoagulation Alone for Proliferative Diabetic Retinopathy.

Author(s)
Warda Ali Department of Eye, Shifa College of Medicine / Shifa Tameere- Millat University, Islamabad, Pakistan
Kanwal Zareen Abbasi Department of Eye, Benazir Bhutto Hospital, Rawalpindi, Pakistan
Ali Raza Department of Eye, RMC and Allied Hospitals Rawalpindi, Pakistan
Abstract
Objective: To compare panretinal photocoagulation (PRP) plus intravitreal bevacizumab (IVB) against PRP alone in the treatment of proliferative diabetic retinopathy (PDR) in terms of mean change in best corrected visual acuity (BCVA), neovessels on disc (NVD) and neovessels elsewhere (NVE). Study Design: Experimental study. Place and Duration of Study: Department of Ophthalmology, Benazir Bhutto Hospital, Rawalpindi, from December 2014 to July 2015. Methodology: Sixty eyes were randomized into two groups with 30 eyes in each. In group A, IVB was given 15 days prior to PRP but in group B only PRP was given. In both groups, BCVA and neovessels status at disc and elsewhere was assessed before and at day 30. NVDs were judged as per percentage of NVD occupying surface of the disc (DD%). NVE were also judged as per reference to diameter of disc surface. Results: The mean age of the study patients was 52.27 ±6.7 years. Mean BCVA (logMAR) in the PRP plus IVB group improved considerably from mean 0.64 ±0.17 to mean 0.49 ±0.21 at 30th day. However, in PRP group, there was no significant change in BCVA 0.64 ±0.16 at baseline to 0.63 ±0.18 at day 30. There were extremely significant changes between the two groups at 4th week (p<0.001). Mean NVE at baseline in PRP plus group was 3.30 ±0.95% at baseline that changes to 1.50 ±1.06% at day 30. While in only PRP group, mean NVE was 3.33 ±0.7% at baseline and 3.17 ±0.7% at one month of follow-up. In PRP plus group, NVD changes from mean 31.27 ±9.8% at baseline to 11.40 ±5.5% at one month of follow-up. In only PRP group, NVD changes from mean 31.13 ±10.23% at baseline to 29.53 ±11.04% at 1 month of follow-up. There were extremely significant changes between two groups at day 30 (p<0.001). Conclusion: Intravitreal bevacizumab in short duration is effective as adjunctive treatment to PRP with early and greater rate of regression of retinal neovessel than PRP alone in PDR patients.
Publication Details
Page(s) 923-927
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 12, Year: 2018

Request the full text from PASTIC

References
QidwaiW,AshfaqT., 2010.Imminent epidemic of diabetes mellitis in Pakistan: Issues and challenges for health care providers,J Liaquat Univ Med Health Sci 9 112 -3
AhmadM,Jan S, 2012.Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy,J Ayub Med Coll Abbottabad 24 10 -3
Romero-ArocaP., 2013.Current status in diabetic macular edema treatments,World J Diabetes 4 165 -9
MitchellP,WongTY, 2014.Diabetic macular edema treatment guideline working group. Management paradigms for diabetic macular edema,Am J Ophthalmol 157 505 -13
AbuEl-Asrar,AM, 2013.Evolving strategies in the management of diabetic retinopathy,Middle East Afr J Ophthalmol 20 273 -82
TareenIU,RahmanA,MaharPS, 2013.Primary effects of intravitreal bevacizumab in patients with diabetic macular edema,Pak J Med Sci 29 1018 -22
AlRashaed,S , Arevalo,JF, 2013.Combined therapy for diabetic macular edema Middle East,Afr J Ophthalmol 20 315 -20
YangCS,HungKC,HuangYM,HsuWM, 2013.Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy,J Ocul Pharmacol Ther 29 550 -5
ChoWB,OhSB,MoonJW,KimHC, 2009.Panretinal photocoagulation combined with intravitreal bevacizumab in highrisk proliferative diabetic retinopathy,Retina 29 516 -22
PapavasileiouE,DereklisD,OikonomidisP,GrixtiA,Vineeth KumarB,PrasadS., 2014.An effective programme to systematic diabetic retinopathy screening in order to reduce diabetic retinopathy blindness,Hell J Nucl Med 17 30 -4
ShinYW,LeeYJ,LeeBR,ChoHY, 2009.Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy,Korean J Ophthalmol 23 266 -72
JorgeR,CostaRA,CalucciD,CintraLP,ScottIU, 2006.Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study),Retina 26 1006 -13
MatsumotoY,FreundKB,PeirettiE,CooneyMJ,FerraraDC,YannuzziLA, 2007.Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease,Retina 27 426 -31
MirshahiA,RoohipoorR,LashayA,MohammadiSF,AbdoallahiA,FaghihiH, 2008.Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial,Eur J Ophthalmol 18 263 -9
TonelloM,CostaRA,AlmeidaFP,BarbosaJC,ScottIU,JorgeR, 2008.Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study),Acta Ophthalmol 86 385 -9
FilhoJA,MessiasA,AlmeidaFP,RibeiroJA,CostaRA,ScottIU,JorgeR, 2011.Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy,Acta Ophthalmol 89 e567 -72
ArevaloJF,WuL,SanchezJG,MaiaM,SaraviaMJ,FernandezCF, 2009.Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up,Eye (Lond) 23 117 -23
AveryRL,PearlsmanJ,PieramiciDJ,RabenaMD,CastellarinAA,NasirMA, 2006.Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,Ophthalmology 113 e1 -15
ArevaloJF,MaiaM,FlynnHW,SaraviaM,AveryRL,WuL, 2008.Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy,Br J Ophthalmol 92 213 -6
HanXX,GuoCM,LiY,Hui YN, 2012.Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: Reduction of endothelial cells and expressions of VEGF and HIF-1,Mol Vis 18 1 -9
0

Citations

0

Downloads

61

Views